RVMD Stock Jumps As Street Bets On Daraxonrasib

Revolution Medicines Inc – Ordinary Shares surge as pivotal clinical progress and collaborations fuel optimism; stocks have been trading up by 38.74 percent

Live Update At 10:02:49 EDT: On Monday, April 13, 2026 Revolution Medicines Inc – Ordinary Shares stock [NASDAQ: RVMD] is trending up by 38.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RVMD looks like a classic high-expectation biotech story on the tape. Over the past few weeks, Revolution Medicines has marched from the low-$90s to a recent close around $133.79, a sharp move that tells traders money is crowding in ahead of catalysts. The step-change gap from roughly $97 to the mid‑$120s in premarket and early trading shows how fast sentiment flipped once the Street leaned in.

On the daily chart, RVMD has held most of its gains, with dips toward the mid‑$90s repeatedly bought and closes pushing back into the high‑$90s and, most recently, well into triple digits. That is classic accumulation behavior in a catalyst setup.

More Breaking News

• Astera Labs Sees Stock Surges Amidst International Expansion and Strategic Maneuvers
• Rackspace and Rubrik Launch Strategic Ransomware Recovery Solution
• HTZ Stock Grinds Higher As Traders Study Debt And Momentum
• SanDisk Shares Jump as Memory Market Strengthens

Under the hood, RVMD is not a value play. The company posted about -$364.9M in net loss in 2025 with heavy R&D spend near $294.9M. Returns on equity and assets are deep in the red, and the price‑to‑book multiple above 11 shows traders are paying up for future potential, not current earnings. The key offset is balance sheet strength: roughly $2.03B in cash and short‑term investments, a current ratio over 7, and modest long‑term debt around $142.2M. For traders, that cash runway reduces financing risk while the market waits on daraxonrasib data.

Why Traders Are Watching RVMD Now

RVMD is on every biotech momentum screen because the story has shifted from “science project” to “pivotal-stage catalyst machine.” Jefferies fired the opening shot, initiating coverage of Revolution Medicines with a Buy rating and lifting its price target to $140 from $88. The firm highlighted RVMD’s RAS(ON) platform and, more specifically, voiced confidence that the Phase 3 RASolute 302 trial in second‑line pancreatic cancer is likely to succeed at the first interim look. That is strong wording from a major broker and the kind of thing that pulls in aggressive trading capital.

Oppenheimer then piled on, reiterating an Outperform on RVMD with a $150 target versus a recent share price near $93 at the time of that note. The bank expects a positive Phase 3 readout for daraxonrasib in pancreatic cancer in the first half of the year, with the possibility of early trial stoppage and a regulatory filing in the back half. For traders, that is a clean binary setup: defined catalyst window, clear Street narrative, and a sizable implied upside gap if things go right.

Meanwhile, RVMD is not sitting still. The company has kicked off RASolute 303, a global Phase 3 trial testing daraxonrasib alone and with chemo in first‑line metastatic pancreatic ductal adenocarcinoma, enrolling patients regardless of RAS genotype. RVMD has also dosed the first patients in another late‑stage daraxonrasib trial for first‑line metastatic pancreatic disease, bringing its tally to four registrational studies across pancreatic and non‑small cell lung cancer. Add in nine data sets heading to the 2026 AACR meeting — including zoldonrasib in KRAS G12D NSCLC and next‑generation RAS(ON) work — and traders have a steady drumbeat of news to trade around.

Conclusion

For active traders, RVMD is the kind of story that rewards homework and strict risk control. Revolution Medicines is burning cash, posting a quarterly operating loss north of $361.6M and free cash flow around -$276.2M, but it also holds more than $2.02B in cash and short‑term investments to keep the R&D engine running. The whole RVMD thesis on the Street right now centers on daraxonrasib and the broader RAS(ON) pipeline moving through multiple Phase 3 shots on goal.

The bullish analyst calls — $140 from Jefferies and $150 from Oppenheimer — signal that larger players are willing to model meaningful commercial value for RVMD’s programs before approval. At the same time, insider selling in March 2026 by the CEO, R&D chief, COO, and commercialization head, even with large remaining holdings, reminds traders not to blindly chase the story. In the end, the chart, the catalysts, and the risk plan matter more than any one opinion. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”, and RVMD is a textbook case where traders need to make sure all those elements line up before taking a position.

As Tim Sykes likes to tell his students, “The market doesn’t care about your feelings, only your plan and your discipline.” RVMD is giving traders the volatility and headlines; it is on each trader to manage position size, respect key levels, and cut losses fast if the data or the tape turns.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.